NCT04802980 is a Phase 1 clinical trial of HB002.1T in Solid Tumor, sponsored by Huabo Biopharm Co., Ltd..

Who is sponsoring NCT04802980?

NCT04802980 is sponsored by Huabo Biopharm Co., Ltd..

What drugs are being tested in NCT04802980?

Interventions in NCT04802980: HB002.1T, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin.

What condition does NCT04802980 study?

NCT04802980 studies Solid Tumor.

Is NCT04802980 still recruiting?

NCT04802980 is currently status unknown. Last updated 26 July 2021.

Last reviewed 2021-07-26 · How we verify

NCT04802980

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase Ib, Multicenter, Open-label, Dose-escalation and Dose-expansion Study of the Safety, Tolerability and Pharmacokinetics of HB002.1T in Combination With Chemotherapy in Patients With Advanced Solid Tumors.

Status unknown Phase 1 Last updated 26 July 2021

What this trial tests

Phase 1 trial testing HB002.1T in Solid Tumor in 72 participants. Status unknown.

Timeline

28 April 2020

Primary endpoint
15 July 2023

1 September 2023

Quick facts

Lead sponsor	Huabo Biopharm Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	72
Start date	28 April 2020
Primary completion	15 July 2023
Estimated completion	1 September 2023
Sites	1 location across China

Drugs / interventions tested

HB002.1T
Oxaliplatin (Oxaliplatin) — full drug profile →
Capecitabine (capecitabine) — full drug profile →
Paclitaxel — full drug profile →
Gemcitabine
Cisplatin (cisplatin) — full drug profile →
Carboplatin

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Huabo Biopharm Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

the Maximum Tolerated Dose (MTD) of HB002.1T
Time frame: up to 3 weeks
Will be determined by dose limiting toxicity. MTD defined as the highest dose level with no more than 1 patient with DLT out of 6 patients that are treated.

Sponsor's own description

The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1T in combination with different chemotherapy regimens administered to patients with advanced solid tumors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Trial watch: chemotherapy-induced immunogenic cell death in oncology.
Sprooten J, Laureano RS, Vanmeerbeek I, Govaerts J, et al · · 2023 · cited 59× · PMID 37284695 · DOI 10.1080/2162402x.2023.2219591

Verify or expand the search:

Other trials of HB002.1T

Trials testing the same drug.

NCT03636750 — A Study of Injection HB002.1T in Subjects With Solid Tumor · Phase 1 · completed

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Huabo Biopharm Co., Ltd. trials

Trials by the same sponsor.

NCT07376629 — A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC · Phase 2 · enrolling by invitation
NCT06592274 — A Phase 2 Study of HB0017 in Psoriasis Patients · Phase 2 · recruiting
NCT06758557 — A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor · Phase 1, PHASE2 · recruiting
NCT06222125 — A Study of HB0025 Injection in Patients With Advanced Renal Cancer · Phase 2 · unknown
NCT05531682 — A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04802980 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huabo Biopharm Co., Ltd.
Last refreshed: 26 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04802980.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing